Bidil: Recontextualizing the race debate

Pharmacogenomics Journal

Volumn 8, Issue 3, 2008, Pages 169-173

  Seguin B ^a   Hardy, B ^a,b   Singer, P A ^a,b   Daar, A S ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; BAZEDOXIFENE; BIFIDIL; CORONARY VASODILATING AGENT; DG 031; DONEPEZIL; ENTECAVIR; HERPES VACCINE; HERPEVAC; HYDRALAZINE PLUS ISOSORBIDE DINITRATE; MOTAVIZUMAB; NEBIVOLOL; NUMAX TM; ROSUVASTATIN; VELIFLAPON;

AFRICAN AMERICAN; ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL; DRUG COST; DRUG EFFICACY; DRUG FORMULATION; DRUG MARKETING; ETHNOPHARMACOLOGY; EVIDENCE BASED MEDICINE; FOOD AND DRUG ADMINISTRATION; HEALTH CARE ACCESS; HEALTH CARE POLICY; HEALTH CARE QUALITY; HEART FAILURE; HEPATITIS B; HERPES; HIGH RISK POPULATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MENOPAUSAL SYNDROME; MINORITY GROUP; PHARMACOGENOMICS; PRIORITY JOURNAL; REIMBURSEMENT; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; VIRUS INFECTION;

AFRICAN AMERICANS; CLINICAL TRIALS AS TOPIC; CONTINENTAL POPULATION GROUPS; DRUG APPROVAL; DRUG COMBINATIONS; HEART FAILURE; HUMANS; HYDRALAZINE; ISOSORBIDE DINITRATE; PHARMACOGENETICS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 44049087291     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/sj.tpj.6500489     Document Type: Article

References (41)

1. Taylor AL, Ziesche S, Yancy C, Carson P, D'Agostino Jr R, Ferdinand K et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004; 351: 2049-2057.
2. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG et al, ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to update the 2001 guidelines for the evaluation and management of heart failure): Developed in collaboration with the American College of chest physicians and the international society for heart and lung transplantation: Endorsed by the heart rhythm society. Circulation 2005; 112: E154-e235.
3. Syre S. Nitromed's challenge. The Boston Globe 2006 Boston Capital.
4. Carson P, Ziesche S, Johnson G, Cohn JN. Racial differences in response to therapy for heart failure: Analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group. J Card Fail 1999; 5: 178-187.
5. Cheng JW. A review of isosorbide dinitrate and hydralazine in the management of heart failure in black patients, with a focus on a new fixed-dose combination. Clin Ther 2006; 28: 666-678.
6. Elkayam U, Bitar F. Effects of nitrates and hydralazine in heart failure: Clinical evidence before the African-American heart failure trial. Am J Cardiol 2005; 96: 37i-43i.
7. Franciosa JA, Taylor AL, Cohn JN, Yancy CW, Ziesche S, Olukotun A et al. African-American heart failure trial (A-HeFT): Rationale, design, and methodology. J Card Fail 2002; 8: 128-135.
8. Taylor AL. The African-American Heart Failure Trial: A clinical trial update. Am J Cardiol 2005; 96: 44-48.
9. Taylor AL. The African-American Heart Failure Trial (A-HeFT): Rationale and methodology. J Card Fail 2003; 9: S216-S219.
10. Temple R, Stockbridge NL. BiDil for heart failure in black patients: The US food and drug administration perspective. Ann Intern Med 2007, 146: 57-62.
11. Daar AS, Scherer SW, Hegele RA. Implications of copy-number variation in the human genome: A time for questions. Nat Rev Genet 2006; 7 414.
12. Daar AS, Singer PA. Pharmacogenetics and geographical ancestry: implications for drug development and global health. Nat Rev Genet 2005; 6: 241-246.
13. Daar AS, Thorsteinsdottir H, Martin DK, Smith AC, Nast S, Singer PA. Top ten biatechnologies for improving health in developing countries. Nat Genet 2002; 32: 229-232.
14. Bibbins-Domingo K, Fernandez A. BiDil for heart failure in black patients: Implications of the US food and drug administration approval. Ann Intern Med 2007;. 146: 52-56.
15. Bloche MG. Race, money and medicines. J Law Med Ethics 2006; 34 555-558, 480.
16. Bowser R. Race as a proxy for drug response: The dangers and challenges of ethnic drugs. De Paul Low Rev 2004; 53: 1111-1126.
17. Brody H, Hunt LM. BiDil: Assessing a racebased pharmaceutical. Ann Fam Med 2006; 4: 556-560.
18. Carlson RJ. The case ot BiDil: A policy commentary on race and genetics. Health Aff (Millwood) 2005 Suppl Web Exclusives: W5-464-8.
19. Haga SB, Ginsburg GS. Prescribing BiDil: Is it black and white? J Am Coll Cordial 2006; 48: 12-14.
20. Kahn J. Patenting race. Nat Biotechnol 2006; 24: 1349-1351.
21. Kahn J. How a drug becomes 'ethnic': Law, commerce, and the production of racial categories in medicine. Yale J Health Policy Law Ethics 2004; 4: 1-46.
22. Kahn J. Race, pharmacogenomics, and marketing: Putting BiDil in context. Am Bioeth 2006; 6: W1-W5.
23. Lee SS. The ethical implications of stratifying by race in pharmacogenomics. Clin Pharmacol Ther 2007; 81: 122-125.
24. O'Malley P. Ethnic pharmacology: Science, research, race, and market share. Clin Nurse Spec 2005; 19: 291-293.
25. Puckrein G. BiDil: From another vantage point. Health Aff (Millwood 2006; 25: W368-w374.
26. Rahemtulla T, Bhopal R. Pharmacogenetics and ethnically targeted therapies. BMJ 2005; 330: 1036-1037.
27. Sankar P, Kahn J. BiDil: Race medicine or race marketing? Health Aff (Millwood) 2005 Suppi Web Exclusives: W5-455-63.
28. Senior K. Drugs tailored to race move a step closer to reality. Drug Discov Today 2005; 10: 1076-1077.
29. Taylor AL, Wright Jr JT. Should ethnicity serve as the basis for clinical trial design? Importance of race/ethnicity in clinical trials: lessons frorrf the African-American heart failure trial (A-HeFT), the African-American study of kidney disease and hypertension (AASK), and the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). Circulation 2005; 112: 3654-3660; discussion 3666.
30. Food and Drug Administration. Food and drug modernization act of 1997 (PL 105-115). PL 1997: 105-115.
31. National Institutes of Health. NIH revitalization act of 1993 (PL 103-43). PL 1993: 103-143.
32. Lybecker KM. The economic fundamentals of the US pharmaceutical market. Manag Care 2004; 13: 7-9; discussion 12-3, 41-2.
33. Winstein KJ. Politics and economics: NAACP presses US on heart drug. Wall St J 2007; A20: 20.
34. McNamara DM, Tam SW, Sabolinsid ML, Tobelmann P, Janosko K, Taylor AL et al. Aldosterone synthase promoter polymorphism predicts outcome in African Americans with heart failure: Results from the A-HeFT trial. J Am Coll Cordiol 2006; 48: 1277-1282.
35. Hakonarson H, Thorvaldsson S, Helgadottir A, Gudbjartsson D, Zink F, Andresdottir M et al. Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction: A randomized trial. JAMA 2005; 293: 2245-2256.
36. http://www.clinicaltrials.gov/ct/show/NCT00353067?order=1.
37. http://www.decode.com/Pipeline/MI.php.
38. Helgadottir A, Manolescu A, Helgason A, Thorleifsson G, Thorsteinsdottir U, Gudbjartsson DF et al. A variant of the gene encoding leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial infarction. Nat Genet 2006; 38: 68-74.
39. Ting H. Confronting ethnicity-specific disease risk. Nat Genet 2006; 38: 13-15.
40. Rothstein MA, Epps PG. Ethical and legal implications of pharmacogenomics. Nat Rev Genet 2001; 2: 228-231.
41. Po AL. Personalised medicine: Who is an Asian? Lancet 2007; 369 1770-1771.